FRANKLIN STREET ADVISORS INC /NC - PROQR THRAPEUTICS N V ownership

PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 47 filers reported holding PROQR THRAPEUTICS N V in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
FRANKLIN STREET ADVISORS INC /NC ownership history of PROQR THRAPEUTICS N V
ValueSharesWeighting
Q3 2023$195
-19.8%
150,0000.0%0.02%
-19.0%
Q2 2023$243
-24.1%
150,0000.0%0.02%
-27.6%
Q1 2023$320
-42.3%
150,0000.0%0.03%
-45.3%
Q4 2022$555
-99.5%
150,0000.0%0.05%
+381.8%
Q3 2022$112,000
-4.3%
150,0000.0%0.01%0.0%
Q2 2022$117,000
+28.6%
150,000
+50.0%
0.01%
+57.1%
Q1 2022$91,000
-89.7%
100,000
-9.1%
0.01%
-89.6%
Q4 2021$881,000
+5.3%
110,000
+10.0%
0.07%
-5.6%
Q3 2021$837,000
+24.2%
100,0000.0%0.07%
+24.6%
Q2 2021$674,000
+2.0%
100,0000.0%0.06%
-6.6%
Q1 2021$661,000
+162.3%
100,000
+66.7%
0.06%
+154.2%
Q4 2020$252,000
-12.2%
60,0000.0%0.02%
-22.6%
Q3 2020$287,000
-21.4%
60,0000.0%0.03%
-27.9%
Q2 2020$365,000
+10.9%
60,0000.0%0.04%
-10.4%
Q1 2020$329,000
-44.7%
60,0000.0%0.05%
-31.4%
Q4 2019$595,000
+72.0%
60,0000.0%0.07%
+59.1%
Q3 2019$346,000
-36.6%
60,0000.0%0.04%
-37.1%
Q2 2019$546,000
-34.4%
60,0000.0%0.07%
-39.7%
Q1 2019$832,000
-12.1%
60,0000.0%0.12%
-22.7%
Q4 2018$947,000
-18.4%
60,0000.0%0.15%
-4.5%
Q3 2018$1,161,000
+76.7%
60,000
-33.3%
0.16%
+63.5%
Q2 2018$657,000
+255.1%
90,000
+50.0%
0.10%
+242.9%
Q1 2018$185,00060,0000.03%
Other shareholders
PROQR THRAPEUTICS N V shareholders Q3 2023
NameSharesValueWeighting ↓
M28 Capital Management LP 1,910,600$2,483,7802.85%
Privium Fund Management B.V. 5,344,446$6,947,7802.07%
DAFNA Capital Management LLC 940,582$1,222,7570.38%
Monaco Asset Management SAM 377,517$490,7720.15%
EcoR1 Capital, LLC 2,980,016$3,874,0210.13%
Ikarian Capital, LLC 472,625$614,4120.07%
FRANKLIN STREET ADVISORS INC /NC 150,000$1950.02%
ADAGE CAPITAL PARTNERS GP, L.L.C. 3,625,467$4,713,1070.01%
GSA CAPITAL PARTNERS LLP 74,084$960.01%
UBS OCONNOR LLC 189,328$246,1260.01%
View complete list of PROQR THRAPEUTICS N V shareholders